ClinConnect ClinConnect Logo
Search / Trial NCT00388271

Use of Alfuzosin in Stone Treatment With ESWL

Launched by SINGAPORE GENERAL HOSPITAL · Oct 13, 2006

Trial Information

Current as of June 14, 2025

Withdrawn

Keywords

Alpha Blocker Alfuzosin Xatral Eswl

ClinConnect Summary

Urinary tract stones may form in the kidneys or along the ureteric tracts and when left untreated, may result in complications such as pain, bleeding, infection and obstruction. ESWL (extra-corporeal shock wave lithotripsy) has been shown to be an effective and safe method of treatment for kidney and ureteric stones in-situ. In our centre, ESWL is done on an outpatient basis with oral pain killers in the weeks following treatment. Patients are also instructed to increase their fluid intake during this period to expedite the clearance of stone fragments. Alpha1-adrenergic blockers have been ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • All adult patients referred to our centre for ESWL treatment of renal or ureteric stones who give their informed consent.
  • Exclusion Criteria:
  • Documented allergy or severe side effects to opioids/ NSAIDs/ Alfuzosin Severe hydronephrosis (on ultrasound or IVU) Radiolucent stones Urinary tract infections Previous pyeloureteral surgery Lower pole stones DJ stents in situ for stones Known renal/hepatic impairment or coagulopathy Pregnant Severe skeletal disease

About Singapore General Hospital

Singapore General Hospital (SGH) is a leading academic medical center in Singapore, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SGH plays a pivotal role in conducting cutting-edge studies that aim to improve patient outcomes and enhance medical knowledge across various specialties. With a strong focus on collaboration and multidisciplinary approaches, SGH leverages its extensive resources and expertise to facilitate rigorous clinical trials, ensuring the highest standards of safety and efficacy in the development of new treatments and therapies.

Locations

Singapore, , Singapore

Patients applied

0 patients applied

Trial Officials

Tsung Wen Chong, MBBS, FRCS

Principal Investigator

SGH Urology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials